Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.11+0.06 (+1.48%)
Close on Nov 18, 2026Market cap $813.16MP/E 5.3Yield –
Arbutus Biopharma gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Arbutus Biopharma
Arbutus Biopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?